Jonathan Sandoval, PhD
Postdoctoral Scholar
Cellular Molecular Pharmacology
School of Medicine

Publications (5)

Top publication keywords:
Epigenesis, GeneticCyclin-Dependent Kinase Inhibitor p15Mutation, MissenseGene Expression Regulation, LeukemicPyridazinesMutationLeukemia, Myeloid, AcuteTumor Suppressor Protein p53PyrazolonesNucleosomesDNA Modification MethylasesDNA (Cytosine-5-)-MethyltransferasesDNA MethylationThymine DNA GlycosylaseAllosteric Site

• First-in-Class Allosteric Inhibitors of DNMT3A Disrupt Protein-Protein Interactions and Induce Acute Myeloid Leukemia Cell Differentiation.
  Journal of medicinal chemistry 2022 Sandoval JE, Ramabadran R, Stillson N, Sarah L, Fujimori DG, Goodell MA, Reich N
• A novel class of selective non-nucleoside inhibitors of human DNA methyltransferase 3A.
  Bioorganic & medicinal chemistry letters 2021 Huang S, Stillson NJ, Sandoval JE, Yung C, Reich NO
• p53 and TDG are dominant in regulating the activity of the human de novo DNA methyltransferase DNMT3A on nucleosomes.
  The Journal of biological chemistry 2020 Sandoval JE, Reich NO
• The R882H substitution in the human de novo DNA methyltransferase DNMT3A disrupts allosteric regulation by the tumor supressor p53.
  The Journal of biological chemistry 2019 Sandoval JE, Reich NO
• Mutations in the DNMT3A DNA methyltransferase in acute myeloid leukemia patients cause both loss and gain of function and differential regulation by protein partners.
  The Journal of biological chemistry 2019 Sandoval JE, Huang YH, Muise A, Goodell MA, Reich NO